

World Journal of *Gastroenterology*

World J Gastroenterol 2017 July 21; 23(27): 4847-5040





EDITORIAL

- 4847 Evolving role of the endoscopist in management of gastrointestinal neuroendocrine tumors

Yazici C, Boulay BR

- 4856 Current research and treatment for gastrointestinal stromal tumors

Lim KT, Tan KY

REVIEW

- 4867 Significance of dormant forms of *Helicobacter pylori* in ulcerogenesis

Reshetnyak VI, Reshetnyak TM

MINIREVIEWS

- 4879 Prognostic significance of red blood cell distribution width in gastrointestinal disorders

Goyal H, Lippi G, Gjymishka A, John B, Chhabra R, May E

- 4892 Endoscopic ultrasound-guided radiofrequency ablation in gastroenterology: New horizons in search

Chaudhary S, Sun SY

ORIGINAL ARTICLE

Basic Study

- 4897 Genetic association and epistatic interaction of the interleukin-10 signaling pathway in pediatric inflammatory bowel disease

Lin Z, Wang Z, Hegarty JP, Lin TR, Wang Y, Deiling S, Wu R, Thomas NJ, Floros J

- 4910 Generation of glyceraldehyde-derived advanced glycation end-products in pancreatic cancer cells and the potential of tumor promotion

Takata T, Ueda T, Sakasai-Sakai A, Takeuchi M

- 4920 Anti-oxidant and anti-inflammatory effects of hydrogen-rich water alleviate ethanol-induced fatty liver in mice

Lin CP, Chuang WC, Lu FJ, Chen CY

- 4935 Human liver chimeric mouse model based on diphtheria toxin-induced liver injury

Ren XN, Ren RR, Yang H, Qin BY, Peng XH, Chen LX, Li S, Yuan MJ, Wang C, Zhou XH

Retrospective Study

- 4942 Perinatal transmission in infants of mothers with chronic hepatitis B in California

Burgis JC, Kong D, Salibay C, Zipprich J, Harriman K, So S

- 4950** Outcome of a session of extracorporeal shock wave lithotripsy before endoscopic retrograde cholangiopancreatography for problematic and large common bile duct stones

Tao T, Zhang M, Zhang QJ, Li L, Li T, Zhu X, Li MD, Li GH, Sun SX

Prospective Study

- 4958** Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease

Netz U, Carter JV, Eichenberger MR, Dryden GW, Pan J, Rai SN, Galandiuk S

- 4968** New formula for predicting standard liver volume in Chinese adults

Feng LM, Wang PQ, Yu H, Chen RT, Wang J, Sheng X, Yuan ZL, Shi PM, Xie WF, Zeng X

- 4978** Postoperative decrease of serum albumin predicts short-term complications in patients undergoing gastric cancer resection

Liu ZJ, Ge XL, Ai SC, Wang HK, Sun F, Chen L, Guan WX

SYSTEMATIC REVIEW

- 4986** Management of inflammatory bowel disease with *Clostridium difficile* infection

D'Aoust J, Battat R, Bessissow T

META-ANALYSIS

- 5004** Effect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysis

de Avelar CR, Pereira EM, de Farias Costa PR, de Jesus RP, de Oliveira LPM

- 5018** High expression of anti-apoptotic protein Bcl-2 is a good prognostic factor in colorectal cancer: Result of a meta-analysis

Huang Q, Li S, Cheng P, Deng M, He X, Wang Z, Yang CH, Zhao XY, Huang J

CASE REPORT

- 5034** Liver injury after aluminum potassium sulfate and tannic acid treatment of hemorrhoids

Yoshikawa K, Kawashima R, Hirose Y, Shibata K, Akasu T, Hagiwara N, Yokota T, Imai N, Iwaku A, Kobayashi G, Kobayashi H, Kinoshita A, Fushiya N, Kijima H, Koike K, Saruta M

Contents

World Journal of Gastroenterology
Volume 23 Number 27 July 21, 2017

ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Takeshi Ogura, MD, PhD, Associate Professor, 2nd Department of Internal Medicine, Osaka Medical College, Takatsukishi 464-8681, Japan

AIMS AND SCOPE

World Journal of Gastroenterology (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7th, 14th, 21st, and 28th each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

INDEXING/ABSTRACTING

World Journal of Gastroenterology (*WJG*) is now indexed in Current Contents[®]/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch[®]), Journal Citation Reports[®], Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2017 edition of Journal Citation Reports[®] cites the 2016 impact factor for *WJG* as 3.365 (5-year impact factor: 3.176), ranking *WJG* as 29th among 79 journals in gastroenterology and hepatology (quartile in category Q2).

FLYLEAF

I-IX Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Dan Li*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Ze-Mao Gong*
Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print)
ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF

Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

Stephen C Strom, PhD, Professor, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

EDITORIAL BOARD MEMBERS

All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

EDITORIAL OFFICE

Jin-Lei Wang, Director
Yuan Qi, Vice Director
Ze-Mao Gong, Vice Director
World Journal of Gastroenterology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER

Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>

<http://www.wjgnet.com>

PUBLICATION DATE
July 21, 2017

COPYRIGHT

© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS

Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION
<http://www.f6publishing.com>

Significance of dormant forms of *Helicobacter pylori* in ulcerogenesis

Vasiliy Ivanovich Reshetnyak, Tatiana Magomedalieva Reshetnyak

Vasiliy Ivanovich Reshetnyak, VA Negovsky Research Institute of General Reanimatology of Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, 107031 Moscow, Russia

Tatiana Magomedalieva Reshetnyak, Department of Systemic Connective Tissue Diseases, VA Nasonova Research Institute of Rheumatology, 115522 Moscow, Russia

Author contributions: Reshetnyak VI and Reshetnyak TM contributed equally to the writing of this manuscript.

Conflict-of-interest statement: Reshetnyak VI and Reshetnyak TM declare no conflicts of interest exist in relation to this publication.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Correspondence to: Vasiliy Ivanovich Reshetnyak, MD, PhD, DSc, Professor, Academic Secretary of VA Negovsky Research Institute of General Reanimatology of Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, 25-2, Petrovka Street, 107031 Moscow, Russia. vasiliy.reshetnyak@yandex.ru
Telephone: +7-495-6946505
Fax: +7-495-6946505

Received: March 30, 2017

Peer-review started: April 8, 2017

First decision: April 21, 2017

Revised: May 3, 2017

Accepted: June 18, 2017

Article in press: June 19, 2017

Published online: July 21, 2017

Abstract

Nearly half of the global population are carriers of *Helicobacter pylori* (*H. pylori*), a Gram-negative bacterium that persists in the healthy human stomach. *H. pylori* can be a pathogen and causes development of peptic ulcer disease in a certain state of the macro-organism. It is well established that *H. pylori* infection is the main cause of chronic gastritis and peptic ulcer disease (PUD). Decontamination of the gastric mucosa with various antibiotics leads to *H. pylori* elimination and longer remission in this disease. However, the reasons for repeated detection of *H. pylori* in recurrent PUD after its successful eradication remain unclear. The reason for the redetection of *H. pylori* in recurrent PUD can be either reinfection or ineffective anti-*Helicobacter* therapy. The administration of antibacterial drugs can lead not only to the emergence of resistant strains of microorganisms, but also contribute to the conversion of *H. pylori* into the resting (dormant) state. The dormant forms of *H. pylori* have been shown to play a potential role in the development of relapses of PUD. The paper discusses morphological *H. pylori* forms, such as S-shaped, C-shaped, U-shaped, and coccoid ones. The authors propose the classification of *H. pylori* according to its morphological forms and viability.

Key words: *Helicobacter pylori*; Forms of *H. pylori*; Dormant forms of *H. pylori*; Viable forms of *H. pylori*; Non-viable forms of *H. pylori*; Physiological states of *H. pylori*; Culturable forms of *H. pylori*; Unculturable forms of *H. pylori*; Resuscitation of dormant *H. pylori*; Ulcerogenesis

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: The administration of antisecretory and antibacterial drugs can lead to the conversion of *Helicobacter pylori* (*H. pylori*) into the resting (dormant) state. C-shaped and U-shaped forms of *H. pylori*, most likely, are dormant forms of the bacteria. C-shaped

and U-shaped forms of *H. pylori* are capable of reverse transition into the vegetative replicative state and of causing development of recurrence of peptic ulcer disease (PUD). The induction of process reversion occurs under the influence of specific molecules. The identification and study of these compounds will allow development of new drugs aimed at preventing recurrent PUD associated with dormant forms of *H. pylori*.

Reshetnyak VI, Reshetnyak TM. Significance of dormant forms of *Helicobacter pylori* in ulcerogenesis. *World J Gastroenterol* 2017; 23(27): 4867-4878 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i27/4867.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i27.4867>

INTRODUCTION

Peptic ulcer disease (PUD) is a problem that is traditionally the center of attention of gastroenterologists^[1]. Many aspects of this pathology have been well studied. The disease develops as a result of the influence of a set of various exogenous and endogenous etiological factors. There are many theories of PUD development, including vascular, inflammatory-gastritis, allergic, hormonal, motor-primacy, corticovisceral, neurogenic, psychosomatic, acido-peptic and infectious ones. Each of them deserves attention, as it reflects one of the facets of this complex problem. The diversity of the causes that lead to the pathological process allows PUD to be considered as a polyetiological and polypathogenic disease.

PUD with a frequently recurrent or long-term healing ulcer of the stomach or duodenum generally occurs in the presence of chronic active gastritis or chronic active duodenitis, both of which are associated with *Helicobacter pylori* (*H. pylori*) infection. Decontamination of the gastric mucosa (GM) with various antibiotics results in *H. pylori* eradication and longer remission in PUD^[2-6]. However, the reasons for repeated detection of *H. pylori* in relapsed PUD after its supposedly successful eradication remain unclear. This may be due to either reinfection or ineffective anti-*Helicobacter* therapy. In most cases, the administration of antibacterial drugs leads to complete *H. pylori* eradication, but can give rise to resistant bacterial strains and facilitate the conversion of *H. pylori* into the resting (dormant) forms^[7]. It is therefore relevant to study dormant *H. pylori* forms, as well as their values in ulcerogenesis^[8].

H. PYLORI IS ONE OF THE ETIOLOGICAL FACTORS OF PUD

Landmarks in the history of *H. pylori* studies

The accumulated scientific data can confirm that

H. pylori infection is important in the mechanism of PUD development^[9]. *H. pylori* was first reported in 1875 when Bottcher and Letulle observed it on the margins of peptic ulcers^[10]. The bacterium did not grow in the artificial nutrient media that were known at that time, and this accidental discovery was long forgotten. In the 1980s, Australian pathologist Robin Warren together with Barry Marshall isolated *H. pylori* from human gastric mucosal biopsy specimens and cultured it in artificial nutrient media. Warren and Marshall suggested that most gastric ulcers and gastritis in humans might be associated with *H. pylori* infection^[11,12]. Marshall demonstrated the role of *H. pylori* infection in the development of gastrointestinal diseases in 1983. He drank a culture of the bacterium to prove the etiological role of *H. pylori* in the development of antral gastritis. Thereafter, he developed *H. pylori*-associated antral gastritis. After that, many researchers concentrated on the study of *H. pylori*^[13].

There has been gradually increasing evidence that duodenal ulcers and duodenitis are also associated with *H. pylori* infection^[14-16]. In 2005, Warren and Marshall received the Nobel Prize in Physiology or Medicine for the discovery of *H. pylori* pathogenicity^[12] and rekindled interest in the study of this microorganism. Since then, the association of *H. pylori* with digestive system diseases has been the subject of much research attention^[10,16].

Risk of digestive system diseases caused by *H. pylori*

H. pylori is one of the most common infections worldwide. *H. pylori* infection is highly prevalent throughout the world, especially in developing countries^[10]. Nearly half of the global population are carriers of *H. pylori*, a Gram-negative bacterium that persists in the human stomach and duodenum^[12,17-21]. *H. pylori* gastric colonization is acquired early in life (almost always before the age of 10 years), and, in the absence of antibiotic therapy, generally persists for life^[12,22,23]. The prevalence of *H. pylori* ranges from 35% to 90% in different populations^[21,24-28]. It presents in 70%-90% of the population in developing countries and 35%-40% in developed ones^[21,29].

Moscow falls into a group of cities with extremely high *H. pylori* infection prevalence, with the predominance of virulent bacterial strains^[30]. It is reported that 88% of the Moscow working population is infected with *H. pylori*. Its prevalence is 78% in people younger than 30 years and about 97% in individuals older than 60 years^[30]. The prevalence of *H. pylori* infection is high in developing countries, especially among children. In India, the prevalence of this infection is 22%, 56% and 87% in the 0-4, 5-9 and 10-19 year age groups, respectively^[21,31]. *H. pylori* is usually the numerically dominant gastric microorganism^[13]. However, PUD occurs only in a small percentage of *H. pylori* carriers^[32].

H. pylori does not typically cause any adverse




Figure 1 Morphology of *Helicobacter pylori*. S-shaped *H. pylori* with five to seven sheathed polar flagella. Field emission SEM, bar = 0.5 μm . (Field emission SEMs courtesy of L. Thompson and negative stains courtesy of S. Danon, School of Microbiology and Immunology, University of New South Wales). From: *Helicobacter pylori*: Physiology and Genetics. Mobley HLT, Mendz GL, Hazell SL, editors. Washington (DC): ASM Press; 2001. Chapter 6, Morphology and Ultrastructure^[54].

effects^[13]. Many people infected with *H. pylori* are shown to remain asymptomatic carriers^[33]. It has turned out that *H. pylori* may behave as a commensal or symbiont, depending upon the circumstances^[34-37]. The idea that *H. pylori* might actually confer benefits to humans has engendered considerable controversy among investigators. The data of the potential importance of health benefits that might be afforded by *H. pylori* are considered and debated in the review by Cover and Blaser^[13]. It has been presumed that the conserved microbiota have specific adaptations that permit persistence at particular locales^[13].

In the 1980-1990s, researchers studied the role of *H. pylori* as an important factor in the etiopathogenesis of PUD. Human gastric colonization by the bacterium *H. pylori* is a predisposing factor for gastrointestinal diseases, such as gastritis and PUD^[13,38]. Strong links exist between PUD and *H. pylori* infection^[39]. So, *H. pylori* detection rates in PUD vary from 60% to 100%. There is also a strong relationship between *H. pylori* and duodenal ulcer^[21]. *H. pylori* has been shown to be one of the important local factors involved in the development of ulcerative defect^[40,41]. The manifestations associated with chronic *H. pylori* infection vary considerably among distinct geographic regions and these differences have been attributed at least in part to polymorphisms of *H. pylori* genes, particularly those encoding virulence factors^[15]. *H. pylori* is an important gastrointestinal pathogen associated with gastritis, PUD, and an increased risk of gastric carcinoma^[22]. The presence of *H. pylori* in the gastroduodenal mucosa and its involvement in the development of chronic gastritis, PUD, carcinoma and other diseases are well documented^[9,15,23,42].

Blaser considers that *H. pylori* shows its pathogenicity, by regulating the expression of different genes to the extent that is dictated by the response of a macroorganism^[13,43]. The microorganism and

macroorganism create a finely tuned balance system, the resulting impairment of which develops a specific disease with certain clinical signs and prognosis^[44]. In the vast majority of cases, long-lasting *H. pylori* infection induces chronic gastritis, while only some patients develop PUD and gastric cancer. For this reason, the bacterium is considered to be a risk factor for the development and recurrence of PUD^[45,46]. Therefore, *H. pylori* is assigned to the group of pathogenic bacteria. Antibiotic treatment of PUD results in bacterial disappearance and ulcer healing^[12]. Marshall and Warren reported that eradication of the bacteria significantly reduced the duodenal ulcer relapse rate^[12].

Characteristics of *H. pylori*

The genus *Helicobacter* (helix and bacteria) is heterogeneous^[47]. The *Helicobacter* genus now includes at least 26 formally named species, and more that are still being studied^[48,49]. Some of them were previously known by other names. Humans have been found to have only 11 *Helicobacter* species: *H. pylori*, *H. heilmannii*, and *H. felis* in the GM, *H. cinaedi* (*H. westmeadii*, *H. canadensis*), *H. fennelliae*, *H. canis*, *H. pullorum*, and *H. rappini* in the small intestinal mucosa. Some *Helicobacter* species have been isolated from the human hepatobiliary system: *H. pylori* from the liver, *H. bilis*, *H. pullorum*, and *H. rappini* from the bile ducts. *H. pylori* is the best known bacterium. *H. pylori* includes several strains^[46]. *H. pylori* strains isolated from unrelated humans exhibit a high level of genetic diversity (reviewed in Blaser MJ and Berg DE^[50]). The genetic structure of the pathogenic genes of *H. pylori* varies largely, which contributes to the differences in virulence among various strains and in clinical symptoms^[15]. *H. pylori* strains differ in resistance to drugs, adhesive specificity and production of cytotoxins.

H. pylori (Figure 1) is a small, Gram-negative, asporogenous, S-shaped or slightly spirally curved, microaerophilic bacterium^[51-53].

Thirty-seven degrees Celsius and pH 4.0-6.0 are the most favorable conditions for the life, growth, and reproduction of *H. pylori*; although, the species also survives at pH 2.5. *H. pylori* *in vivo* and under optimum *in vitro* conditions exists as an S-shaped bacterium with 1 to 3 turns, 0.5 μm \times 5 μm in length, and a tuft of 5 to 7 polar sheathed flagella^[54-56]. The bacterial cell is covered with a smooth sheath. The flagellum of *H. pylori* is 30 nm in diameter, consisting of an internal filament approximately 12 nm in diameter surrounded by a sheath, the outer membrane of which is continuous with the outer membrane of the cell^[54-56].

Unipolar flagella are essential for the unique motility of *H. pylori*^[57]. Qin *et al.*^[57] employed cryo-electron tomography to visualize intact *H. pylori* cells, with a particular focus on the flagella. Remarkably, the unipolar flagella of *H. pylori* are driven by one of the largest flagellar motors found in bacteria. The flagellar motor provides




Figure 2 Microscopic images of coccoid forms of *Helicobacter pylori* after 6-d exposure to antibiotics. From: Faghri *et al*^[65].

higher torque needed by the bacterium to navigate the viscous environment of the human stomach. Thin sections of *H. pylori* reveal the typical cell wall detail of a Gram-negative bacterium that consists of outer and inner, or plasma, membranes separated by the periplasm of approximately 30 nm thickness^[54]. *H. pylori* has inherent corkscrew motility. The presence of flagella, a smooth cell sheath, a spiral shape, and corkscrew motility allows this microorganism to move in the mucus thickness along the pH gradient and serves as its virulence factor. In addition, the flagella contribute to the aggregation of *H. pylori* to colonize the latter on the epithelial surface of GM^[58].

The stomach is the major habitat of *H. pylori*^[13], but it may also survive in other environments^[13,18,59]. The habitat of *H. pylori* may be the proximal duodenum or distal esophagus. This is usually accompanied by gastric metaplasia at these sites^[13]. A gene that is pathognomonic for duodenal ulcer and called *dupA* (duodenal ulcer promoting gene), which encompasses the two *H. pylori* genes of *jhp0917* and *jhp0918*, has been discovered^[60]. This gene increases the survival of the microorganism at low pH values. The presence of the *dupA* gene is associated with a high risk for duodenal ulcer and with a low risk for gastric atrophy and cancer^[61].

COCCHOID AND DORMANT FORMS OF *H. PYLORI*

Morphological forms of H. pylori

All living organisms are equipped with mechanisms that allow extended survival in adverse environments. For a number of them, this response involves, besides metabolic adaptations, changes in cell morphology^[62]. *H. pylori* is mainly present as a spiral-shaped form in human gastric biopsy specimens. On aging, the bacterial cells lose their typical spiral-shaped form and convert to coccoid ones (Figure 2)^[54]. When influenced by adverse factors (temperature or pH changes, prolonged fasting when cultivated, or use of antibacterial drugs), non-spore-forming microorganisms

can be transformed into a latent coccoid form^[63].

The ability of *H. pylori* to transform from the spiral-shaped form to the coccoid form is one of its most important, but not exclusive properties. Through the course of evolution, *H. pylori* has evolved special adaptive mechanisms and acquired vital physiological properties allowing it to survive extreme situations in the human organism, when cultivated, and to survive in the external environment^[64].

The bacterium transforms from spiral to coccoid under mild circumstances, whereas under extreme ones it is unable to undergo shape modification. This strongly supports the view that transformation into the coccoid form is an active, biologically led process, switched on by the bacterium as a protection mechanism^[62,65]. This study demonstrates that the coccoid shape is in fact a manifestation of cell adaptation to less than optimum environments.

Saito *et al*^[66] identified three types of coccoid forms of *H. pylori*. The authors claim to represent different *H. pylori* transformation processes and consist of bacteria that are dead, living and cultivated, and viable but non-culturable^[62,66]. Controversy exists as to whether these cells are viable, dormant or just dead^[54].

The initial stage of *H. pylori* transformation in the coccoid form is accompanied by the condensation of the protoplasmic matrix and an increase in the periplasm on one side of the microorganism (usually at the pole opposite to the flagellar basal complex). An increase in the volume of the periplasmic space leads to stretching of the cell wall, displacement of the protoplasmic matrix to the periphery, and accumulation of dense material, that results in the formation of C-shaped and/or U-shaped cells (Figure 3)^[54].

These C-shaped and/or U-shaped forms then convert to the coccoid cells, with an increase in the protoplasmic cylinder and maintenance of the double membrane system (Figures 3 and 4)^[54]. In their work, Mouery *et al*^[67] have shown transmission electron micrographs of typical stages of the helical-to-coccoid transformation. C-shaped and/or U-shaped forms of *H. pylori* are an intermediate state of the bacteria^[67-69].

The C-shaped and/or U-shaped forms of *H. pylori* are an intermediate bacterial type transforming into an inactive phase (dormancy). Dormancy is understood to be a reversible state of bacterial cells with a low metabolic activity, in which they can be for a long time without replication^[63,70,71]. In microbiology, this condition has, until recently, been associated with the presence of forms, such as spores and cysts. In the late 20th century, the literature began to discuss the possibility of formation of dormant (resting) forms by non-spore-forming bacteria^[63,72] that encompass most Gram-negative pathogenic bacteria, including *H. pylori*. Dormancy is characterized by the increased resistance of bacterial cells to extreme stresses (deficiency of nutrients, effects of antiseptic drugs, antibiotics, etc.) and favors their survival^[73]. The ability




Figure 3 Microscopic images of morphological forms of *Helicobacter pylori* after exposure to antibiotics: S-shaped, U-shaped, C-shaped and coccoid-shaped. From: Faghri *et al.*^[65].




Figure 4 Electronograms of coccoid forms of *Helicobacter pylori*. A: Initial ingrowth in the periplasmic space resulting in the formation of U-shaped cells; B: Conversion to the coccoid form. Ultrathin section, bar = 0.5 μ m. From: *Helicobacter pylori*: Physiology and Genetics. Mobley HLT, Mendz GL, Hazell SL, editors. Washington (DC): ASM Press; 2001. Chapter 6, Morphology and Ultrastructure^[54].

of *H. pylori* to go into a dormant state may be an important factor in the epidemiology and spread of helicobacteriosis. The C-shaped and U-shaped forms of *H. pylori* can be considered truly a dormant form capable of reinfection^[53]. The role of these forms in the pathogenesis and transmission of infection needs to be clarified.

The C-shaped and/or U-shaped forms of *H. pylori* keep the polar membrane associated with the flagellar basal complex^[56,65]. Only a small number of intermediate forms of *H. pylori* possesses a complete

set of flagella and retains metabolic activity to ensure mobility comparable to that of spiral-shaped forms^[68].

The fully-formed coccoid forms maintain the basic pattern of a bacterial cell structure (Figure 4). They have a cell wall, cytoplasmic membrane and cytoplasm^[56,62,67,69,74]. The coccoid cells differ in details of the cell wall structure, which leads to impairment of recognition of the bacteria by the host immune system (bacterial mimicry)^[68].

The accumulated scientific data suggest that there are three morphological forms of *H. pylori*: (1) S-shaped forms; (2) U-shaped and C-shaped (intermediate or transitional) forms; and (3) Coccoid forms.

The intermediate and coccoid forms can coexist in the mucosa or in the culture in various ratios^[75]. Their ratio depends on the time of *H. pylori* being present under adverse conditions and on the level of exposure to adverse factors. Spiral-shaped forms were predominant in a 3-d culture of *H. pylori*; about half of the bacteria are coccoid forms at 6 d^[76-78]. Mouery *et al.*^[67] show the graphical distribution of the ratio of morphological forms of *H. pylori* after 12, 24 and 48 h of cultivation. The distributions of morphologies of more than 100 cells of each genotype for each time point are shown^[67]. The number of coccoid forms increases with the longer time of cultivation. This happens due to the transition of C-shaped and U-shaped forms of *H. pylori* to coccoid ones.

The C-shaped, U-shaped and coccoid forms of *H. pylori* lose enzyme activity and show a lower metabolism^[79]. The urease activities of resting (dormant) and coccoid cells were found to be lower than those of the spiral-shaped form of *H. pylori*^[80,81]. A significant transformation of *H. pylori* into coccoid forms may result in loss of urease activity. However, urease-encoding genes continue to be identified in *H. pylori* by polymerase chain reaction (PCR)^[69,81,82]. The minimization of enzyme activity and energy metabolism in the transformable *H. pylori* forms is adaptive and aimed at preserving the viability of microorganisms^[65,83]. Bacterial viability has been confirmed by the fact that the transformed forms of *H. pylori* can be detected by acridine orange staining^[69,84]. The C-shaped, U-shaped and coccoid forms of *H. pylori* tolerate a wider pH range to a greater extent than the spiral-shaped forms, are resistant to unfavorable factors and antibiotics, and cannot lose virulence. All this creates favorable conditions for the preservation of bacteria in the human body or in the external environment.

The triggers of *H. pylori* transformation from spiral-shaped to coccoid forms in the environment may be physical factors: higher insolation, low humidity, and lack of food substrates^[77,85]. During bacteriological cultivation, transformation into the coccoid forms occurs due to the depletion of adequate components of the nutrient medium^[85,86]. *H. pylori* transforms in the human body due to changes in the habitat conditions upon exposure to antisecretory and antibacterial

Table 1 Detection of *Helicobacter pylori* in gastric mucosa biopsy specimens from in-patients with duodenal ulcer by quantitative urease test and polymerase chain reaction before and one month after anti-*Helicobacter* therapy

Detection of <i>Helicobacter pylori</i>	Quantitative urease test	PCR	Difference between methods
Before treatment, %	93.4	98.7	5.3
After treatment, %	11.1	24.1	13.0

PCR: Polymerase chain reaction.

drugs. Khomeriki *et al*^[69] have studied the time course of changes in the transformation of *H. pylori* in the GM. They have indicated that the spiral-shaped forms transform into the coccoid ones a few hours after adhesion to the cell surface of GM cells^[69].

The conversion of the spiral forms of *H. pylori* to its C-shaped, U-shaped and coccoid forms in the GM and in the nutrient medium is due to the accumulation of toxic metabolic products of *H. pylori* vital functions. Reactive oxygen species generated by phagocytes or by *H. pylori* itself in the presence of specific pyridine nucleotides may trigger the formation of transitional and coccoid forms in the GM of untreated patients^[69]. When an unfavorable situation occurs, there is accumulation of factors that induce the conversion of cells in the bacterial populations to a dormant state.

Loginov *et al*^[8] carried out a comparative analysis in which *H. pylori* in GM biopsy specimens from patients with duodenal ulcer was detected by a quantitative urease test and PCR before and a month after anti-*Helicobacter* therapy. Prior to anti-*Helicobacter* therapy, the detection rate of *H. pylori* in the GM biopsy specimens from patients with PUD was 93.4% and 98.7%, as shown by the quantitative urease test and PCR, respectively (Table 1). The difference of 5.3% in the detection rate of *H. pylori* may be due to the different sensitivities of these methods.

One month after eradication therapy, these patients had *H. pylori* detected by the quantitative urease test in 11.1% of cases and by PCR in 24.1%. The difference between the methods was 13%, *i.e.*, almost twice that as before the treatment. These findings suggest that *H. pylori* were not completely eliminated in some patients at 1 mo after the anti-*Helicobacter* therapy, and the *H. pylori* diagnosed by PCR were at least partially in a dormant (resting) state and partly in coccoid forms. The low urease activity (or lack thereof) of coccoid *H. pylori* forms precludes identifying them by the quantitative urease test. The data presented allow us to indirectly suggest that after anti-*Helicobacter* therapy, the dormant forms of *H. pylori* are present in patients as a result of their incomplete elimination^[7,87].

Viability of dormant and coccoid forms of *H. pylori*

The pleiomorphic nature of *H. pylori* has been the subject of intensive debate for many years, with part of the scientific community arguing that the coccoid

shape represents a degraded, nonviable form of the cell^[62,85,86,88-91]. Evidence supporting the concept that the coccoid forms are degenerate and not capable of growth comes from a number of studies showing that as the cells age, the levels of DNA and RNA and mRNA expression decrease with degradation of the nucleic acids, nonrandom fragmentation of the ribosomal RNA, and no evidence of a membrane potential necessary for processes such as oxidative phosphorylation^[54]. There is evidence that the coccoid forms lose their reproductive ability, are unculturable in artificial nutrient media, have no characteristic features under a light microscope, and do not produce urease or produce it in low amounts^[65,79,81,86,92,93]. The infectivity of coccoid *H. pylori* forms is still controversial^[94].

There are opposing data regarding the viability of the C-shaped, U-shaped and coccoid form of *H. pylori*. A study by Khomeriki and Morozov^[69] indicated that the structural transformation of spiral-shaped forms of *H. pylori* into the coccoid forms is not always a sign of functional disintegration of the microorganism. There is evidence confirming the viability of the transformed forms of *H. pylori*^[81]. They maintain cell structure, exhibit respiratory activity, support protein metabolism and expression, and, in some cases, are capable of reverse transition into the vegetative spiral-shaped bacteria (on their passage through animals)^[92]. Cell respiration is detected in up to 40% after 45 d *in vitro* cultivation of *H. pylori*^[54,95-97]. The findings of Poursina *et al*^[94] suggest that the induced coccoid form of *H. pylori* is not a passive entity but can actively infect a human by expression of the virulence genes after a long stay in the stomach and may contribute to the development of chronic and severe disease. Flow cytometry analyses show that the majority of the induced coccoids (90%-99.9%) are viable^[94].

There is evidence of the viability of the transformed forms of *H. pylori* obtained using biochemical methods. The cultures consisting of intermediate and coccoid forms have been found to retain oxidative metabolism at the same level as spiral-shaped forms for several months^[98]. They maintain a high level of alkaline and acid phosphatases and a stable ATP level that increases if a number of fresh nutrient medium is added to the old culture^[80-82,99]. Incorporation of a bromodeoxyuridine label into the transformed forms is suggestive of their continuing synthesis of new DNA^[65,69]. So far, it is unconfirmed whether these data indicate the viability of *H. pylori* or the persistence of cells as "bags of enzymes"^[98].

The contradictory data on the viability of the transformable forms of *H. pylori* are likely due to the fact that *H. pylori* coexists in coccoid and transitional (intermediate C-shaped and U-shaped) forms under unfavorable conditions in the human body or culture media. It is impossible to isolate data on the viability of intermediate and coccoid forms co-existing in the same culture. Apparently, one part of transformed cells in the population of *H. pylori* truly is degenerative,




Figure 5 Major physiological states and forms of *Helicobacter pylori*^[101]. *H. pylori*: *Helicobacter pylori*.

dead cells^[100] (most likely it is the coccoid forms), and the other is dormant cells, reversible forms (most likely it is the C-shaped and U-shaped forms). There is evidence confirming the concept of viability of *H. pylori* dormant forms that indicate saving of cellular integrity and DNA synthesis in 3-mo-old cultures^[54].

Available literature data may suggest the existence of the following conditions for various forms of *H. pylori* (Figure 5): (1) Viable and culturable (spiral-shaped forms of *H. pylori*) states; (2) Dormant (resting) and culturable (most likely it is the C-shaped and U-shaped forms of *H. pylori*) states; and (3) Non-viable and unculturable (most likely it is the coccoid forms of *H. pylori*) states.

However, there are not enough solid data to associate the particular morphological type (C-shaped, U-shaped and coccoid forms) of *H. pylori* with the functional characteristics of viability and culturability^[65]. As a rule, the literature presents data on the viability of either spiral or coccoid forms. When describing the latter, the presence of dormant (transitional, intermediate, resting) forms is not generally taken into account. The C-shaped and U-shaped forms of *H. pylori* are most likely in a dormant (resting) state and can be a viable and culturable (Figure 5)^[101].

And if so, once under favorable conditions, the dormant (resting) forms of *H. pylori* can revert to a vegetative spiral-shaped form. By using electron microscopy, Konstantinova *et al.*^[102] have shown that there are various defects in the cell wall of the transformed forms of *H. pylori*. The authors point out that before the reversion of the dormant forms of *H.*

pylori to vegetative forms, there is a need for certain conditions for the repair of cellular damages.

"Reanimated" *H. pylori* can play an important role in the development of recurrent PUD after anti-*Helicobacter* treatment^[81,96]. The "revived" forms of *H. pylori* are able to colonize the GM to subsequently develop peptic ulcer relapse^[78,95]. Continuation of investigations in this area may reveal new important aspects of the pathogenesis of *H. pylori* infection and to find new ways to treat diseases associated with this microorganism^[69,89,96].

Figure 5 suggests a classification of major physiological states and forms of *H. pylori* that is a hypothetical scheme and requires further evidence. Existing conflicting data on viability and culturability of various forms of *H. pylori* fit well with this scheme and pass into the category of comparable data.

DORMANT FORMS OF *H. PYLORI* IN THE DEVELOPMENT OF RECURRENT PUD

The main challenge is to prove the reversion of transformable forms of *H. pylori* into a normal replicative state. There is still no clear separation between the true "revivals" of transformed forms of *H. pylori* that are usually present in the population and secondary infection with the microorganism.

Genetic typing of the same strain of the microorganism has become possible with advances in molecular diagnosis. By using the PCR-based restriction fragment length polymorphism (PCR-RFLP) analysis,

H. pylori strains in patients with duodenal ulcer were genotyped before and 1 mo after anti-*Helicobacter* therapy with incomplete elimination^[7,8,87,103,104]. The *flaA* gene (1.5 kb in size) encoding the flagellar protein is one of the polymorphic ones in *H. pylori*. This gene is used in genetic typing of *H. pylori* strains. Identical *H. pylori* strains were detected in the same patient before and after the anti-*Helicobacter* therapy. At that, heterogeneous *H. pylori* strains were found in different patients. The given data suggested that there was neither superinfection nor reinfection with a new strain at 1 mo after anti-*Helicobacter* therapy.

Warren and Marshall reported that eradication of the bacteria markedly reduced the relapse rate of duodenal ulcer^[12]. *H. pylori* eradication decreases the recurrence rate of PUD from 50% to 0%-10% of cases per year^[105]. Current treatment modalities allow eradication of the *H. pylori* bacterium in up to 90% of cases (less if there is clarithromycin resistance)^[106]. During the first years after effective anti-*Helicobacter* therapy, the rate of *H. pylori* reinfection in adults is 0%-35%^[107]. The rate of *H. pylori* reinfection varies according to geographical area^[106]. Reinfection in developed countries is less common, in 0%-7% of cases^[108]. In regions with higher socioeconomic status and lower prevalence of *H. pylori*, it is only 1.68% of cases^[106]. The *H. pylori* reinfection rate in Lithuania is relatively high (the annual rate being 3.36%), probably because of the high prevalence of *H. pylori*^[105]. This could indirectly reflect differences in the socioeconomic status between Western and Eastern European countries^[106]. In contrast, in developing countries, the reinfection rate could be much higher and has been reported to reach 9.63%^[106,109,110].

In some cases, recrudescence or reinfection of *H. pylori* may occur^[106]. According to Loginov *et al.*^[7], 18.4% of *H. pylori*-positive patients were identified among those with *H. pylori*-associated duodenal ulcer a year after successful treatment. The recurrence rate of PUD in these patients was 14.3%, which comprised 2.6% of the total number of patients included in the study patients. Reinfection of *H. pylori* is observed rarely and occurs during later periods. Reinfection is considered when *H. pylori* is found after confirmed *H. pylori* eradication. *H. pylori* strains genetically different from the original ones are generally identified in reinfection.

PCR-RFLP was used to detect *H. pylori* strains in patients with duodenal ulcer before and 1 year after anti-*Helicobacter* therapy^[7,103,104]. *H. pylori* strains were genotyped by the *flaA* gene. Genetic typing of *H. pylori* strains revealed both cases of the same strain of the bacterium in a patient before and 1 year after anti-*Helicobacter* therapy, as well as cases of its different strains. Gastroduodenoscopy (EGD) at 1 year after treatment revealed that all *H. pylori*-positive patients had a pattern of exacerbation of chronic antral gastritis. At that, 1 mo after anti-*Helicobacter* therapy,

these patients were found to have no signs of any gastric and duodenal changes during EGD.

Identification of the pattern of chronic antral gastritis and different strains of the bacterium a year after anti-*Helicobacter* therapy performed in patients with duodenal ulcer could reveal a case of reinfection with a new *H. pylori* strain in the patient successfully treated against *H. pylori*. Identification of the pattern of chronic antral gastritis and the same strain of *H. pylori* a year after anti-*Helicobacter* therapy in patients with duodenal PUD most likely suggests that the bacterium is transformed from a dormant (resting) state into the vegetative form. Hence, for successful therapy, it is essential not only to eradicate the spiral forms of *H. pylori*, but to eliminate its viable dormant forms.

Factors contributing to the transformation of dormant (resting) forms of bacteria into the vegetative ones

Mukamolova *et al.*^[111] have identified specific bacterial cytokines from *Mycobacterium tuberculosis*, *Mycobacterium avium*, *Micrococcus luteus*, etc., and showed their important role in the activation and reproduction of the dormant forms of the bacterium^[111-114]. Cultivation of *M. luteus* in the presence of a small number of colony-forming cells in the starving population has been ascertained to greatly facilitate the resuscitation of dormant cells^[115]. The authors have suggested that the viable cells are able to secrete certain substances promoting the transition of dormant forms into an active reproduction state^[111,112,116]. A 16-17 kDa protein, named resuscitation-promoting factor (Rpf), has been isolated^[112-115]. The protein promoted the "revival" of the starving cells and reduced the lag phase of an active culture in both the depleted and enriched nutrient media. Using *M. luteus* as an example, Rpf has been shown to stimulate the "reanimation" of dormant cells. Rpf is a pheromone and belongs to the bacterial cytokines^[111].

Structural changes in the reversion of coccoid forms of *H. pylori* in the vegetative state have not been studied and their triggers are unknown. There is no evidence that there are cytokine factors for the activation of *H. pylori* reversion and growth. The slightly acidic environment (pH of 5 to 3.5) is known to be a factor that activates the process of protein synthesis in *H. pylori*. Interestingly, in acting on coccoid and spiral-shaped forms, the same acidic pH values induce the synthesis of various proteins in them^[78,117]. Some of the *H. pylori* proteins, heat shock protein (Hsp) in particular, have a trophic effect on the bacteria themselves and can cause rearrangement of the cell cytoskeleton, which may be a trigger for the reverse transformation of dormant forms into vegetative ones. Hsp synthesis is enhanced under the influence of a number of environmental factors.

These subcellular proteins belong to the chaperones essential for viability of the entire cellular profile of

proteins involved in the processes of assembling for a variety of high-molecular-weight proteins^[118]. *H. pylori* possesses two of the most studied chaperones: HspA (smaller) and HspB (larger), which are associated with urease assembling. HspA differs in its properties from analogous proteins of other bacteria. Being strong antigens, *H. pylori* chaperones take a certain part in the activation of lymphocytes, the regulation of cytokine and chemokine expression, the induction of apoptosis, etc. However, heat shock proteins play a much more important role in the induction of an autoimmune response due to the fact that they are highly antigenically similar to the orthologic structures of the GM^[119]. It is possible that cytokine factors of the macroorganism can play an important role in the activation of bacterium dormant forms.

CONCLUSION

It is necessary to continue studies aimed at identifying specific cytokines or other metabolites of *H. pylori*, which are able to activate the transition of dormant forms of the microorganism into the vegetative spiral state. This will be able to design new anti-Helicobacter drugs to prevent the activation of dormant *H. pylori* forms, as well as recurrent duodenal ulcer.

ACKNOWLEDGMENTS

The authors thank Professor Pisarev VM for helpful discussions.

REFERENCES

- Graham DY. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. *World J Gastroenterol* 2014; **20**: 5191-5204 [PMID: 24833849 DOI: 10.3748/wjg.v20.i18.5191]
- Sakurai K, Suda H, Ido Y, Takeichi T, Okuda A, Hasuda K, Hattori M. Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. *World J Gastroenterol* 2017; **23**: 668-675 [PMID: 28216974 DOI: 10.3748/wjg.v23.i4.668]
- Lin LC, Hsu TH, Huang KW, Tam KW. Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials. *World J Gastroenterol* 2016; **22**: 5445-5453 [PMID: 27340362 DOI: 10.3748/wjg.v22.i23.5445]
- Ghotaslou R, Leylabadlo HE, Asl YM. Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review. *World J Methodol* 2015; **5**: 164-174 [PMID: 26413490 DOI: 10.5662/wjm.v5.i3.164]
- Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: Past, present and future. *World J Gastrointest Pathophysiol* 2014; **5**: 392-399 [PMID: 25400982 DOI: 10.4291/wjgp.v5.i4.392]
- Reshetniak VI, Dudik TV, Solov'eva NA, Zhukhovitskii VG, Il'chenko AA, Kaprel'yants AS. [Eradication of Helicobacter pylori in patients with duodenal ulcer following the short course of treatment with azitromycin and amoxicillin]. *Antibiot Khimioter* 2002; **47**: 16-19 [PMID: 12087718]
- Loginov AS, Reshetniak VI, Mukamolova GV, Fedukova NG, Il'chenko AA, Dudik TV, Kaprel'yants AS. [The possibility of Helicobacter pylori being present in the resting state in the gastric mucosa of peptic acid patients after treatment]. *Ter Arkh* 1999; **71**: 13-16 [PMID: 10222545]
- Loginov AS, Reshetnyak VI, Dudik TV, Vostroknutova GN, Il'chenko AA, Kaprel'yants AS. Diagnostic methods for detecting forms and strains of Helicobacter pylori and evaluation of its eradication. *Bull Exp Biol Med* 2001; **132**: 802-806 [PMID: 11713571]
- Testerman TL, Morris J. Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. *World J Gastroenterol* 2014; **20**: 12781-12808 [PMID: 25278678 DOI: 10.3748/wjg.v20.i36.12781]
- Fernandes YC, Bonatto Gda R, Bonatto MW. Recurrence rate of Helicobacter pylori in patients with peptic ulcer five years or more after successful eradication. *Arq Gastroenterol* 2016; **53**: 152-155 [PMID: 27438419 DOI: 10.1590/S0004-28032016000300006]
- Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet* 1984; **1**: 1311-1315 [PMID: 6145023 DOI: 10.1016/S0140-6736(84)91816-6]
- Steensma DP, Kyle RA, Shampo MA. J. Robin Warren: Helicobacter pylori and peptic ulcer. *Mayo Clin Proc* 2016; **91**: e129-e130 [PMID: 27594194 DOI: 10.1016/j.mayocp.2016.01.027]
- Cover TL, Blaser MJ. Helicobacter pylori in health and disease. *Gastroenterology* 2009; **136**: 1863-1873 [PMID: 19457415 DOI: 10.1053/j.gastro.2009.01.073]
- Siddique I, Al-Qabandi A, Al-Ali J, Alazmi W, Memon A, Mustafa AS, Junaid TA. Association between Helicobacter pylori genotypes and severity of chronic gastritis, peptic ulcer disease and gastric mucosal interleukin-8 levels: Evidence from a study in the Middle East. *Gut Pathog* 2014; **6**: 41 [PMID: 25279005 DOI: 10.1186/s13099-014-0041-1]
- Chen YL, Mo XQ, Huang GR, Huang YQ, Xiao J, Zhao LJ, Wei HY, Liang Q. Gene polymorphisms of pathogenic Helicobacter pylori in patients with different types of gastrointestinal diseases. *World J Gastroenterol* 2016; **22**: 9718-9726 [PMID: 27956795 DOI: 10.3748/wjg.v22.i44.9718]
- Kidd M, Modlin IM. A century of Helicobacter pylori: paradigms lost-paradigms regained. *Digestion* 1998; **59**: 1-15 [PMID: 9468093 DOI: 10.1159/00007461]
- Suerbaum S, Michetti P. Helicobacter pylori infection. *N Engl J Med* 2002; **347**: 1175-1186 [PMID: 12374879 DOI: 10.1056/NEJMra020542]
- van Amsterdam K, van Vliet AH, Kusters JG, van der Ende A. Of microbe and man: determinants of Helicobacter pylori-related diseases. *FEMS Microbiol Rev* 2006; **30**: 131-156 [PMID: 16438683 DOI: 10.1111/j.1574-6976.2005.00006.x]
- Cellini L, Grande R, Di Campli E, Di Bartolomeo S, Di Giulio M, Traini T, Trubiani O. Characterization of an Helicobacter pylori environmental strain. *J Appl Microbiol* 2008; **105**: 761-769 [PMID: 18410343 DOI: 10.1111/j.1365-2672.2008.03808.x]
- Rudnicka K, Graczykowski M, Tenderenda M, Chmiela M. [Helicobacter pylori morphological forms and their potential role in the transmission of infection]. *Postepy Hig Med Dosw (Online)* 2014; **68**: 219-229 [PMID: 24662790 DOI: 10.5604/17322693.1092705]
- Mohammed SA. Prevalence of Helicobacter pylori among patients with different gastrointestinal disorders in Saudi Arabia. *Med J Indones* 2017; **25**: 214 [DOI: 10.13181/mji.v25i4.1442]
- Brown LM. Helicobacter pylori: epidemiology and routes of transmission. *Epidemiol Rev* 2000; **22**: 283-297 [PMID: 11218379 DOI: 10.1093/oxfordjournals.epirev.a018040]
- Perry S, de la Luz Sanchez M, Yang S, Haggerty TD, Hurst P, Perez-Perez G, Parsonnet J. Gastroenteritis and transmission of Helicobacter pylori infection in households. *Emerg Infect Dis* 2006; **12**: 1701-1708 [PMID: 17283620 DOI: 10.3201/eid1211.060086]
- Júnior R, Fernandes AB, Santos FSD, Silva JHG, Loiola RPD, Silva JG, Pereira JO. Soroprevalência da infecção por Helicobacter pylori em uma amostra rural do Estado do Amazonas, Brasil Rev Pan-Amazônica de Saúde 2012; **3**: 33-36

- 25 **Fonseca FM**, Etchebehere RM, Oliveira AG. Helicobacter pylori infection in patients undergoing upper endoscopy at University Hospital in Uberaba, Minas Gerais, Brazil. *JMPHC* 2013; **4**: 33-35
- 26 **Oliveira JG**, Ferreira CH, Camerin AC, Rota CA, Meurer L, Silveira TR. Prevalence of infection with cagA-positive Helicobacter pylori strains among children and adolescents in southern Brazil. *Arq Gastroenterol* 2014; **51**: 180-185 [PMID: 25296076 DOI: 10.1590/S0004-28032014000300003]
- 27 **Bor S**, Kitapcioglu G, Kasap E. Prevalence of gastroesophageal reflux disease in a country with a high occurrence of Helicobacter pylori. *World J Gastroenterol* 2017; **23**: 525-532 [PMID: 28210089 DOI: 10.3748/wjg.v23.i3.525]
- 28 **Wijetunge S**, Kotakadeniya R, Noordeen F, Buharideen SM, Samarasinghe B, Dharmapala A, Galketiya KB. Prevalence of Helicobacter pylori in benign gastric ulcers in a cohort of Sri Lankan patients. *Ceylon Med J* 2015; **60**: 152-154 [PMID: 26778396 DOI: 10.4038/cmj.v60i4.8224]
- 29 **Eusebi LH**, Zagari RM, Bazzoli F. Epidemiology of Helicobacter pylori infection. *Helicobacter* 2014; **19** Suppl 1: 1-5 [PMID: 25167938 DOI: 10.1111/hel.12165]
- 30 **German SV**, Zykova IE, Modestova AV, Yermakov NV. [Prevalence of infection Helicobacter pylori in Moscow population]. *Russian J Gastroenterol, Hepatol, Coloproctol* 2010; **20**: 25-30
- 31 **Das JC**, Paul N. Epidemiology and pathophysiology of Helicobacter pylori infection in children. *Indian J Pediatr* 2007; **74**: 287-290 [PMID: 17401270 DOI: 10.1007/s12098-007-0046-6]
- 32 **Algood HM**, Cover TL. Helicobacter pylori persistence: an overview of interactions between H. pylori and host immune defenses. *Clin Microbiol Rev* 2006; **19**: 597-613 [PMID: 17041136 DOI: 10.1128/CMR.00006-06]
- 33 **Rauws EA**, Tytgat GN. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. *Lancet* 1990; **335**: 1233-1235 [PMID: 1971318 DOI: 10.1016/0140-6736(90)91301-P]
- 34 **Blaser MJ**, Parsonnet J. Parasitism by the "slow" bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. *J Clin Invest* 1994; **94**: 4-8 [PMID: 8040281 DOI: 10.1172/JCI117336]
- 35 **Blaser MJ**. Ecology of Helicobacter pylori in the human stomach. *J Clin Invest* 1997; **100**: 759-762 [PMID: 9259572 DOI: 10.1172/JCI119588]
- 36 **Axon A**. Helicobacter pylori is not a commensal. *Curr Opin Gastroenterol* 1999; **15**: 1-4
- 37 **Blaser MJ**. Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease. *J Infect Dis* 1999; **179**: 1523-1530 [PMID: 10228075 DOI: 10.1086/314785]
- 38 **Blaser MJ**. Helicobacter pylori and gastric diseases. *BMJ* 1998; **316**: 1507-1510 [PMID: 9582144]
- 39 **Ierardi E**, Goni E, Losurdo G, Di Mario F. Helicobacter pylori and nonmalignant diseases. *Helicobacter* 2014; **19** Suppl 1: 27-31 [PMID: 25167942 DOI: 10.1111/hel.12157]
- 40 **Alzahrani S**, Lina TT, Gonzalez J, Pinchuk IV, Beswick EJ, Reyes VE. Effect of Helicobacter pylori on gastric epithelial cells. *World J Gastroenterol* 2014; **20**: 12767-12780 [PMID: 25278677 DOI: 10.3748/wjg.v20.i36.12767]
- 41 **da Costa DM**, Pereira Edos S, Rabenhorst SH. What exists beyond cagA and vacA? Helicobacter pylori genes in gastric diseases. *World J Gastroenterol* 2015; **21**: 10563-10572 [PMID: 26457016 DOI: 10.3748/wjg.v21.i37.10563]
- 42 **Kim A**, Servetas SL, Kang J, Kim J, Jang S, Cha HJ, Lee WJ, Kim J, Romero-Gallo J, Peek RM Jr, Merrell DS, Cha JH. Helicobacter pylori bab Paralogs Distribution and Association with cagA, vacA, and homA/B genotypes in American and South Korean clinical isolates. *PLoS One* 2015; **10**: e0137078 [PMID: 26317221 DOI: 10.1371/journal.pone.0137078]
- 43 **Blaser MJ**. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. *J Infect Dis* 1990; **161**: 626-633 [PMID: 2181029 DOI: 10.1093/infdis/161.4.626]
- 44 **Shkitin VA**, Shpirna AI, Starovoitov GN. [Role of Helicobacter pylori in human pathology]. *Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya* 2002; **4**: 128-145
- 45 **Yamaoka Y**. Pathogenesis of Helicobacter pylori-Related Gastroduodenal Diseases from Molecular Epidemiological Studies. *Gastroenterol Res Pract* 2012; **2012**: 371503 [PMID: 22829807 DOI: 10.1155/2012/371503]
- 46 **Liu J**, He C, Chen M, Wang Z, Xing C, Yuan Y. Association of presence/absence and on/off patterns of Helicobacter pylori oipA gene with peptic ulcer disease and gastric cancer risks: a meta-analysis. *BMC Infect Dis* 2013; **13**: 555 [PMID: 24256489 DOI: 10.1186/1471-2334-13-555]
- 47 **Owen RJ**. Helicobacter-species classification and identification. *Br Med Bull* 1998; **54**: 17-30 [PMID: 9604427 DOI: 10.1093/oxfordjournals.bmb.a011667]
- 48 **Whary MT**, Fox JG. Natural and experimental Helicobacter infections. *Comp Med* 2004; **54**: 128-158 [PMID: 15134359]
- 49 **Mateos-Muñoz B**, Pérez-de-la-Serna J, Ruiz-de-León A, Serrano-Falcón B, Casabona-Francés S, Velasco-Cerrudo A, Rey-Díaz-Rubio E. Enterohepatic Helicobacter other than Helicobacter pylori. *Rev Esp Enferm Dig* 2013; **105**: 477-484 [PMID: 24274445 DOI: 10.4321/S1130-01082013000800006]
- 50 **Blaser MJ**, Berg DE. Helicobacter pylori genetic diversity and risk of human disease. *J Clin Invest* 2001; **107**: 767-773 [PMID: 11285290 DOI: 10.1172/JCI12672]
- 51 **Bardakhch'ian EA**, Lomov Slu, Kharlanova NG, Kamneva NV. [Role of Helicobacter pylori in different extragastroduodenal diseases]. *Eksp Klin Gastroenterol* 2005; **(3)**: 20-27 [PMID: 16255549]
- 52 **Chumpitaz Conde J**, Gutiérrez Manay J, Córdova Acosta R, Sánchez Medina M, Vásquez Valverde N, Rivadeira Malaga C, Beteta Del Carpio O, Solano Mendoza L, Marrocho Chahuayo L, Pareja Cuadros E, Huaman Reyes A, Valencia Bazalar E. [Isolation of helicobacter pylori in dental plaque in patients with gastritis at "Angamos" clinic]. *Rev Gastroenterol Peru* 2006; **26**: 373-376 [PMID: 17211487]
- 53 **Dubois A**. Intracellular Helicobacter pylori and gastric carcinogenesis: an "old" frontier worth revisiting. *Gastroenterology* 2007; **132**: 1177-1180 [PMID: 17383438 DOI: 10.1053/j.gastro.2007.01.068]
- 54 **O'Rourke J**, Bode G. Morphology and ultrastructure (Chapter 6). In: Mobley HLT, Mendz GL, Hazell SL, editors. *Helicobacter pylori: physiology and genetics*. Washington (DC): ASM Press, 2001 Available from: URL: <https://www.ncbi.nlm.nih.gov/books/NBK2452/> [PMID: 21290748]
- 55 **Goodwin CS**, McCulloch RK, Armstrong JA, Wee SH. Unusual cellular fatty acids and distinctive ultrastructure in a new spiral bacterium (Campylobacter pyloridis) from the human gastric mucosa. *J Med Microbiol* 1985; **19**: 257-267 [PMID: 3981612 DOI: 10.1099/00222615-19-2-257]
- 56 **Jones DM**, Curry A, Fox AJ. An ultrastructural study of the gastric campylobacter-like organism 'Campylobacter pyloridis'. *J Gen Microbiol* 1985; **131**: 2335-2341 [PMID: 4067580 DOI: 10.1099/00221287-131-9-2335]
- 57 **Qin Z**, Lin WT, Zhu S, Franco AT, Liu J. Imaging the motility and chemotaxis machineries in Helicobacter pylori by cryo-electron tomography. *J Bacteriol* 2016; Epub ahead of print [PMID: 27849173 DOI: 10.1128/JB.00695-16]
- 58 **Sidebotham RL**, Baron JH. Hypothesis: Helicobacter pylori, urease, mucus, and gastric ulcer. *Lancet* 1990; **335**: 193-195 [PMID: 1967668]
- 59 **Sasaki K**, Tajiri Y, Sata M, Fujii Y, Matsubara F, Zhao M, Shimizu S, Toyonaga A, Tanikawa K. Helicobacter pylori in the natural environment. *Scand J Infect Dis* 1999; **31**: 275-279 [PMID: 10482057]
- 60 **Talebi Bezzmin Abadi A**, Perez-Perez G. Role of dupA in virulence of Helicobacter pylori. *World J Gastroenterol* 2016; **22**: 10118-10123 [PMID: 28028359 DOI: 10.3748/wjg.v22.i46.10118]
- 61 **Makarenko EV**, Voropaeva AV, Matveyenko ME. [The effect of Helicobacter pylori genotypes on morphological parameters of the gastric mucosa in patients with duodenal ulcer and chronic gastritis]. *Vestnik VGMU* 2009; **8**: 88-96
- 62 **Azevedo NF**, Almeida C, Cerqueira L, Dias S, Keevil CW, Vieira

- MJ. Coccoid form of *Helicobacter pylori* as a morphological manifestation of cell adaptation to the environment. *Appl Environ Microbiol* 2007; **73**: 3423-3427 [PMID: 17400788 DOI: 10.1128/AEM.00047-07]
- 63 **Kaprelyants AS**, Gottschal JC, Kell DB. Dormancy in non-sporulating bacteria. *FEMS Microbiol Rev* 1993; **10**: 271-285 [PMID: 8318260]
 - 64 **Bode G**, Mauch F, Malfertheiner P. The coccoid forms of *Helicobacter pylori*. Criteria for their viability. *Epidemiol Infect* 1993; **111**: 483-490 [PMID: 8270008 DOI: 10.1017/S0950268800057216]
 - 65 **Faghri J**, Poursina F, Moghim S, Zarkesh Esfahani H, Nasr Esfahani B, Fazeli H, Mirzaei N, Jamshidian A, Ghasemian Safaei H. Morphological and Bactericidal Effects of Different Antibiotics on *Helicobacter pylori*. *Jundishapur J Microbiol* 2014; **7**: e8704 [PMID: 25147656 DOI: 10.5812/jjm.8704]
 - 66 **Saito N**, Konishi K, Sato F, Kato M, Takeda H, Sugiyama T, Asaka M. Plural transformation-processes from spiral to coccoid *Helicobacter pylori* and its viability. *J Infect* 2003; **46**: 49-55 [PMID: 12504609 DOI: 10.1053/jinf.2002.1047]
 - 67 **Mouery K**, Rader BA, Gaynor EC, Guillemin K. The stringent response is required for *Helicobacter pylori* survival of stationary phase, exposure to acid, and aerobic shock. *J Bacteriol* 2006; **188**: 5494-5500 [PMID: 16855239 DOI: 10.1128/JB.00366-06]
 - 68 **Williams CL**. *Helicobacter pylori*: bacteriology and laboratory diagnosis. *J Infect* 1997; **34**: 1-5 [PMID: 9120318]
 - 69 **Khomeriki SG**, Morozov IA. The role of coccoid forms of *Helicobacter pylori* in pathogenetic mechanisms and persistence of *Helicobacter* infection. *Russian J Gastroenterol, Hepatol, Coloproctol* 2001; **11** Suppl 13: 99-102
 - 70 **Anuchin AM**, Mulyukin AL, Suzina NE, Duda VI, El-Registan GI, Kaprelyants AS. Dormant forms of *Mycobacterium smegmatis* with distinct morphology. *Microbiology* 2009; **155**: 1071-1079 [PMID: 19332809 DOI: 10.1099/mic.0.023028-0]
 - 71 **Kudykina YK**, Shleeva MO, Artsabanov VY, Suzina NE, Kaprelyants AS. [Generation of dormant forms by *Mycobacterium smegmatis* in the poststationary phase during gradual acidification of the medium]. *Mikrobiologiya* 2011; **80**: 625-636 [PMID: 22168006]
 - 72 **Kell DB**, Kaprelyants AS, Weichert DH, Harwood CR, Barer MR. Viability and activity in readily culturable bacteria: a review and discussion of the practical issues. *Antonie Van Leeuwenhoek* 1998; **73**: 169-187 [PMID: 9717575]
 - 73 **Tutelyan AV**, Gaponov AM, Pisarev VM, El-Registan GI. [Microbial dormancy and prevention of healthcare-associated infections]. *Ter Arkh* 2015; **87**: 103-108 [PMID: 26821426 DOI: 10.17116/terarkh20158711103-109]
 - 74 **Sarem M**, Corti R. [Role of *Helicobacter pylori* coccoid forms in infection and recrudescence]. *Gastroenterol Hepatol* 2016; **39**: 28-35 [PMID: 26089229 DOI: 10.1016/j.gastrohep.2015.04.009]
 - 75 **West AP**, Millar MR, Tompkins DS. Survival of *Helicobacter pylori* in water and saline. *J Clin Pathol* 1990; **43**: 609 [PMID: 2199542 DOI: 10.1136/jcp.43.7.609-b]
 - 76 **Catrenich CE**, Makin KM. Characterization of the morphologic conversion of *Helicobacter pylori* from bacillary to coccoid forms. *Scand J Gastroenterol Suppl* 1991; **181**: 58-64 [PMID: 1866596]
 - 77 **Moshkowitz M**, Gorea A, Arber N, Konikoff F, Berger S, Gilat T. Morphological transformation of *Helicobacter pylori* during prolonged incubation: association with decreased acid resistance. *J Clin Pathol* 1994; **47**: 172-174 [PMID: 8132834 DOI: 10.1136/jcp.47.2.172]
 - 78 **Benaissa M**, Babin P, Quillard N, Pezennec L, Cenatiempo Y, Fauchère JL. Changes in *Helicobacter pylori* ultrastructure and antigens during conversion from the bacillary to the coccoid form. *Infect Immun* 1996; **64**: 2331-2335 [PMID: 8675345]
 - 79 **Faizullina RA**, Abdullina EV. Factors of pathogenicity and virulence of *Helicobacter pylori* in the development of *Helicobacter*-associated gastroduodenal pathology. *Prakticheskaya Meditsina* 2011; **1**: 74-78
 - 80 **Nilius M**, Ströhle A, Bode G, Malfertheiner P. Coccoid like forms (CLF) of *Helicobacter pylori*. Enzyme activity and antigenicity. *Zentralbl Bakteriol* 1993; **280**: 259-272 [PMID: 8280950 DOI: 10.1016/S0934-8840(11)80964-3]
 - 81 **Can F**, Karahan C, Dolapci I, Demirbilek M, Tekeli A, Arslan H. Urease activity and urea gene sequencing of coccoid forms of *H. pylori* induced by different factors. *Curr Microbiol* 2008; **56**: 150-155 [PMID: 18167027 DOI: 10.1007/s00284-007-9047-y]
 - 82 **Hua J**, Ho B. Is the coccoid form of *Helicobacter pylori* viable? *Microbios* 1996; **87**: 103-112 [PMID: 9032959]
 - 83 **Jiesong H**, Megraud F. Evidence of the viability of non culturable coccoidal forms of *Helicobacter felis*. *Gut* 1995; **37** Suppl 1: 376
 - 84 **Catrenich CE**, Chestnut MH. Character and origin of vacuoles induced in mammalian cells by the cytotoxin of *Helicobacter pylori*. *J Med Microbiol* 1992; **37**: 389-395 [PMID: 1460658 DOI: 10.1099/00222615-37-6-389]
 - 85 **Sörberg M**, Nilsson M, Hanberger H, Nilsson LE. Morphologic conversion of *Helicobacter pylori* from bacillary to coccoid form. *Eur J Clin Microbiol Infect Dis* 1996; **15**: 216-219 [PMID: 8740856]
 - 86 **Kusters JG**, Gerrits MM, Van Strijp JA, Vandenbroucke-Grauls CM. Coccoid forms of *Helicobacter pylori* are the morphologic manifestation of cell death. *Infect Immun* 1997; **65**: 3672-3679 [PMID: 9284136]
 - 87 **Loginov AS**, Il'chenko AA, Mukamolova GV, Fedukova NG, Dudik TV, Kaprelyants AS, Reshetniak VI. Comparative efficacy of different methods of detecting *H. pylori* in patients with peptic ulcer. *Russ Gastroenterol Zh* 1998; **3**: 3-11
 - 88 **Andersen LP**, Rasmussen L. *Helicobacter pylori*-coccoid forms and biofilm formation. *FEMS Immunol Med Microbiol* 2009; **56**: 112-115 [PMID: 19453756 DOI: 10.1111/j.1574-695X.2009.00556.x]
 - 89 **Bumann D**, Habibi H, Kan B, Schmid M, Goosmann C, Brinkmann V, Meyer TF, Jungblut PR. Lack of stage-specific proteins in coccoid *Helicobacter pylori* cells. *Infect Immun* 2004; **72**: 6738-6742 [PMID: 15501814 DOI: 10.1128/IAI.72.11.6738-6742.2004]
 - 90 **Enroth H**, Wreiber K, Rigo R, Risberg D, Uribe A, Engstrand L. In vitro aging of *Helicobacter pylori*: changes in morphology, intracellular composition and surface properties. *Helicobacter* 1999; **4**: 7-16 [PMID: 10352082 DOI: 10.1046/j.1523-5378.1999.09034.x]
 - 91 **Harvey P**, Leach S. Analysis of coccal cell formation by *Campylobacter jejuni* using continuous culture techniques, and the importance of oxidative stress. *J Appl Microbiol* 1998; **85**: 398-404 [PMID: 9750311 DOI: 10.1046/j.1365-2672.1998.00532.x]
 - 92 **Cellini L**, Allocati N, Angelucci D, Iezzi T, Di Campli E, Marzio L, Dainelli B. Coccoid *Helicobacter pylori* not culturable in vitro reverts in mice. *Microbiol Immunol* 1994; **38**: 843-850 [PMID: 7898382]
 - 93 **Eaton KA**, Catrenich CE, Makin KM, Krakowka S. Virulence of coccoid and bacillary forms of *Helicobacter pylori* in gnotobiotic piglets. *J Infect Dis* 1995; **171**: 459-462 [PMID: 7844390 DOI: 10.1093/infdis/171.2.459]
 - 94 **Poursina F**, Faghri J, Moghim S, Zarkesh-Esfahani H, Nasr-Esfahani B, Fazeli H, Hasanazadeh A, Safaei HG. Assessment of cagE and babA mRNA expression during morphological conversion of *Helicobacter pylori* from spiral to coccoid. *Curr Microbiol* 2013; **66**: 406-413 [PMID: 23263256 DOI: 10.1007/s00284-012-0280-7]
 - 95 **Barer MR**, Gribbon LT, Harwood CR, Nwogu CE. The viable but non-culturable hypothesis and medical microbiology. *Rev Med Microbiol* 1993; **4**: 183-191
 - 96 **Cellini L**, Robuffo I, Di Campli E, Di Bartolomeo S, Taraborelli T, Dainelli B. Recovery of *Helicobacter pylori* ATCC43504 from a viable but not culturable state: regrowth or resuscitation? *APMIS* 1998; **106**: 571-579 [PMID: 9674895]
 - 97 **Donelli G**, Matarrese P, Fiorentini C, Dainelli B, Taraborelli T, Di Campli E, Di Bartolomeo S, Cellini L. The effect of oxygen on the growth and cell morphology of *Helicobacter pylori*. *FEMS Microbiol Lett* 1998; **168**: 9-15 [PMID: 9812358]

- 98 **Gribbon LT**, Barer MR. Oxidative metabolism in nonculturable *Helicobacter pylori* and *Vibrio vulnificus* cells studied by substrate-enhanced tetrazolium reduction and digital image processing. *Appl Environ Microbiol* 1995; **61**: 3379-3384 [PMID: 7574647]
- 99 **Andersen LP**, Dorland A, Karacan H, Colding H, Nilsson HO, Wadström T, Blom J. Possible clinical importance of the transformation of *Helicobacter pylori* into coccoid forms. *Scand J Gastroenterol* 2000; **35**: 897-903 [PMID: 11063146]
- 100 **Mai U**, Geis G, Leying H, Ruhl G, Opferkuch W. Dimorphism of *Campylobacter pylori*. In: Megraud F, Lamuliatte H, editors. *Gastrointestinal pathology and Campylobacter pylori*. Amsterdam: Elsevier Science, 1989: 29-33
- 101 **Kell DB**, Kenny LC. A Dormant Microbial Component in the Development of Preeclampsia. *Front Med (Lausanne)* 2016; **3**: 60 [PMID: 27965958 DOI: 10.3389/fmed.2016.00060]
- 102 **Konstantinova ND**, Zhukhovitskii VG, Didenko LV, Andreevskaya SG. Ultrastructural organization of *Helicobacter pylori* under natural conditions and during ex vivo culturing. *Bull Exp Biol Med* 2001; **131**: 299-301 [PMID: 11427926]
- 103 **Loginov AS**, Kaprel'iants AS, Reshetniak VI, Vostroknutova GN, Dudik TV, Ilchenko AA. On the possibility of genetic typing of *H. pylori* in gastric mucosa biotates. *Russ Gastroenterol Zh* 1999; **4**: 5-9
- 104 **Dudik TV**, Solov'eva NA, Zhukhovitskii VG, Kirillov MIu, Kaprel'iants AS, Reshetniak VI. [Methods of *Helicobacter pylori* detection]. *Russ Gastroenterol Zh* 2001; **(2)**: 77-89 [PMID: 11681191]
- 105 **O'Connor HJ**, Kanduru C, Bhutta AS, Meehan JM, Feeley KM, Cunnane K. Effect of *Helicobacter pylori* eradication on peptic ulcer healing. *Postgrad Med J* 1995; **71**: 90-93 [PMID: 7724441 DOI: 10.1136/pgmj.71.832.90]
- 106 **Jonaitis L**, Kiudelis G, Slepavicius P, Kupcinskas L. High rate of *Helicobacter pylori* reinfection in Lithuanian peptic ulcer patients. *World J Gastrointest Pathophysiol* 2016; **7**: 181-185 [PMID: 26909241 DOI: 10.4291/wjgp.v7.i1.181]
- 107 **Miehlke S**, Lehn N, Meining A, Bästlein E, Mannes GA, Stolte M, Bayerdörffer E. *Helicobacter pylori* reinfection is rare in peptic ulcer patients cured by antimicrobial therapy. *Eur J Gastroenterol Hepatol* 1996; **8**: 1161-1163 [PMID: 8980933 DOI: 10.1097/00042737-199612000-00005]
- 108 **Ivashkin VT**, Megro F, Lapina TL. *Helicobacter pylori*: revolution in gastroenterology. Moscow: Publishing house "Triada-X", 1999; 255
- 109 **Yan TL**, Hu QD, Zhang Q, Li YM, Liang TB. National rates of *Helicobacter pylori* recurrence are significantly and inversely correlated with human development index. *Aliment Pharmacol Ther* 2013; **37**: 963-968 [PMID: 23550618]
- 110 **Harris AW**, Misiewicz JJ, editors. *Helicobacter pylori*. London: Blackwell Healthcare Communication, 1996: 66
- 111 **Mukamolova GV**, Kaprelyants AS, Young DI, Young M, Kell DB. A bacterial cytokine. *Proc Natl Acad Sci USA* 1998; **95**: 8916-8921 [PMID: 9671779 DOI: 10.1073/pnas.95.15.8916]
- 112 **Shleeva MO**, Mukamolova GV, Telkov MV, Berezinskaia TL, Syroeshkin AV, Biketov SF, Kaprel'iants AS. [Formation of nonculturable *Mycobacterium tuberculosis* and their regeneration]. *Mikrobiologiya* 2003; **72**: 76-83 [PMID: 12698796]
- 113 **Mukamolova GV**, Murzin AG, Salina EG, Demina GR, Kell DB, Kaprelyants AS, Young M. Muralytic activity of *Micrococcus luteus* Rpf and its relationship to physiological activity in promoting bacterial growth and resuscitation. *Mol Microbiol* 2006; **59**: 84-98 [PMID: 16359320 DOI: 10.1111/j.1365-2958.2005.04930.x]
- 114 **Shleeva M**, Kondratieva T, Rubakova E, Vostroknutova G, Kaprelyants A, Apt A. Reactivation of dormant "non-culturable" *Mycobacterium tuberculosis* developed in vitro after injection in mice: both the dormancy depth and host genetics influence the outcome. *Microb Pathog* 2015; **78**: 63-66 [PMID: 25434928 DOI: 10.1016/j.micpath.2014.11.016]
- 115 **Votyakova TV**, Kaprelyants AS, Kell DB. Influence of Viable Cells on the Resuscitation of Dormant Cells in *Micrococcus luteus* Cultures Held in an Extended Stationary Phase: the Population Effect. *Appl Environment Microbiol* 1994; **60**: 3284-3291 [PMID: 16349381]
- 116 **Mukamolova GV**, Turapov OA, Kazarian K, Telkov M, Kaprelyants AS, Kell DB, Young M. The Rpf gene of *Micrococcus luteus* encodes an essential secreted growth factor. *Mol Microbiol* 2002; **46**: 611-621 [PMID: 12410820 DOI: 10.1046/j.1365-2958.2002.03183.x]
- 117 **Mizoguchi H**, Fujioka T, Kishi K, Nishizono A, Kodama R, Nasu M. Diversity in protein synthesis and viability of *Helicobacter pylori* coccoid forms in response to various stimuli. *Infect Immun* 1998; **66**: 5555-5560 [PMID: 9784573]
- 118 **Tomb JF**, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD, Ketchum KA, Klenk HP, Gill S, Dougherty BA, Nelson K, Quackenbush J, Zhou L, Kirkness EF, Peterson S, Loftus B, Richardson D, Dodson R, Khalak HG, Glodek A, McKenney K, Fitzgerald LM, Lee N, Adams MD, Hickey EK, Berg DE, Gocayne JD, Utterback TR, Peterson JD, Kelley JM, Cotton MD, Weidman JM, Fujii C, Bowman C, Watthey L, Wallin E, Hayes WS, Borodovsky M, Karp PD, Smith HO, Fraser CM, Venter JC. The complete genome sequence of the gastric pathogen *Helicobacter pylori*. *Nature* 1997; **388**: 539-547 [PMID: 9252185 DOI: 10.1038/41483]
- 119 **Kansau I**, Labigne A. Heat shock proteins of *Helicobacter pylori*. *Aliment Pharmacol Ther* 1996; **10** Suppl 1: 51-56 [PMID: 8730259 DOI: 10.1046/j.1365-2036.1996.22164005.x]

P- Reviewer: Abadi ATB, Kim GH, Yamada S **S- Editor:** Gong ZM
L- Editor: Filipodia **E- Editor:** Zhang FF





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>



ISSN 1007-9327

